Targeting epigenetics for treatment of BRAF mutated metastatic melanoma with decitabine in combination with vemurafenib: A phase lb study

INTRODUCTION: Epigenetic modifications play an important role in progression and development of resistance in (V600E)BRAF positive metastatic melanoma. Therefore, we hypothesized that the action of vemurafenib (BRAF inhibitor) can be made more effective by combining with low dose decitabine (a DNA m...

Descripción completa

Detalles Bibliográficos
Autores principales: Zakharia, Yousef, Monga, Varun, Swami, Umang, Bossler, Aaron D., Freesmeier, Michele, Frees, Melanie, Khan, Mirza, Frydenlund, Noah, Srikantha, Rithu, Vanneste, Marion, Henry, Michael, Milhem, Mohammed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Clinical Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5687680/
https://www.ncbi.nlm.nih.gov/pubmed/29179510
http://dx.doi.org/10.18632/oncotarget.21269

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5687680/
https://www.ncbi.nlm.nih.gov/pubmed/29179510
http://dx.doi.org/10.18632/oncotarget.21269

Ejemplares similares